Tirzepatide reversed weight gain and improved insulin, leptin, and adiponectin levels in a triple-challenge mouse model combining obesity, diabetes, and menopause.
Triple-challenge model reversedTirzepatide improved metabolic outcomes even in mice with the worst possible combination: obesity, diabetes, and estrogen deficiency
What the researchers found
The triple-challenge model (obesity + diabetes + ovariectomy) created the most severe metabolic dysfunction. Obese diabetic ovariectomized mice had more pronounced weight gain slopes than obese diabetic mice with intact ovaries.
Tirzepatide treatment produced negative allometric body weight slopes across treatment time, meaning weight declined consistently. Treated mice showed improved adiponectin (a beneficial fat hormone), insulin levels, and leptin levels. The drug effects were seen in both ovariectomized and sham groups.
Interactions were observed between diet × ovariectomy (affecting weight gain), diet × tirzepatide (affecting weight loss), and diet × ovariectomy × tirzepatide (affecting food intake).
Why it matters
Menopausal women are at high risk for obesity, insulin resistance, and type 2 diabetes due to estrogen loss. This triple-challenge model is more clinically relevant than simple obesity models. Showing that tirzepatide works even with the added challenge of estrogen loss suggests it could be particularly valuable for postmenopausal women with diabetes.
The numbers in context
- 120 mice across multiple groups
- Diet: 12 weeks high-fat/high-sucrose
- Treatment: tirzepatide 10 nmol/kg SC daily for 4 weeks
- Tirzepatide: negative allometric body weight slopes (consistent weight loss)
- Improved: adiponectin, insulin, leptin levels
- Ovariectomy worsened weight gain beyond diet alone
How the study worked
Female C57BL/6 mice (3 months old) underwent bilateral ovariectomy or sham surgery. For 12 weeks, groups received control diet or high-fat/high-sucrose diet (120 mice total across groups). Then tirzepatide (10 nmol/kg subcutaneously daily) or vehicle was administered for 4 additional weeks. Allometric analysis was used to model body weight changes over time.
Who was studied
120 female C57BL/6 mice with diet-induced obesity, diabetes, and bilateral ovariectomy or sham surgery
What this study cannot tell us
This was tested in mice. Ovariectomy in young mice does not perfectly model human menopause, which involves gradual hormonal changes over years. The tirzepatide dose (10 nmol/kg daily) may not directly translate to human dosing. Only 4 weeks of treatment was tested. The allometric analysis is useful for modeling weight trends but does not capture all metabolic endpoints. Human menopause involves more complex hormonal changes than simple estrogen loss.
How to read the evidence
Rated preliminary: well-designed animal study with multiple comparison groups, but ovariectomy in young mice doesn't perfectly model human menopause.
When this study was published
Published in 2024. Addresses an understudied population — post-menopausal women with obesity and diabetes.
The bigger picture
Post-menopausal women face compounded metabolic risk from estrogen loss, weight gain, and insulin resistance. This study provides preclinical evidence that tirzepatide works even in this triple-challenge scenario.
Questions still open
- Does tirzepatide compensate for estrogen loss or work through independent mechanisms?
- Would human post-menopausal women show similar responses?
Common questions
Does tirzepatide work for post-menopausal weight gain?
Why is menopause relevant to diabetes treatment?
Read the original research
The dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice.
Diabetes, obesity & metabolism, 26(10), 4613-4621
Citation
Reis-Barbosa, Pedro H; Marcondes-de-Castro, Ilitch; Marinho, Thatiany S; Aguila, Marcia Barbosa; Mandarim-de-Lacerda, Carlos A. (2024). The dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice.. Diabetes, obesity & metabolism, 26(10), 4613-4621. https://doi.org/10.1111/dom.15820